Managers

Aisling’s Schiff on life sciences investing and today’s investment cycle

Volcanics Venture raises $72.8 mln for venture-capital fund

Volcanics Venture has raised $72.8 million toward a $100 million venture-capital fund, according to a filing with the SEC.

GTP buys into BIG’s software arm, launches Globalive BIGDEV

Globalive Technology Partners (GTP) has acquired a 51 percent stake in the software development arm of Business Instincts Group (BIG), a Calgary venture creation firm led by CEO Cameron Chell. No financial terms were released for the deal, which launches a joint venture called Globalive BIGDEV, a blockchain and machine learning software development and commercialization shop. It has six projects in development, five focused on blockchain and one on artificial intelligence. GTP, unveiled in January by Globalive Capital and the founders of Mundo Inc and VRG Capital, earlier this week announced its going public transaction and $30 million financing.

MassPRIM bets on Polaris Partners debut growth fund

DCM to raise $750 mln for ninth fund

DCM Ventures is seeking to raise $750 million for its ninth fund, according to an SEC filing. With offices in Beijing, Silicon Valley and Tokyo, DCM currently has over $3 billion under management, according to its website.

Pivotal China wraps up initial fund at $150 mln

Pivotal China has closed its inaugural fund at $150 million. Pivotal bioVenture Partners China USD Fund I will focus on incubating and building life sciences companies in China.

Agent Capital collects $57.75 mln for $150 mln-targeted fund

Cambridge, Massachusetts-based Agent Capital, a biotech-focused venture firm, has raised $57.75 million for its initial fund, according to an SEC filing. The target is $150 million.

VC-backed Prevail Therapeutics beefs up board with new addition

New York City-based Prevail Therapeutics Inc, a developer of gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, has named Dr. Francois Nader to its board of directors. Nader was the president, CEO and executive director of NPS Pharma. The investors included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners LP, Boxer Capital LLC, Adage Capital Management LP and Alexandria Venture Investments.

ICO attorneys risk SEC enforcement action

As five VCs predict the future, robotics and AI rise to the surface